Search Results

and acid-base imbalances following hypertonic saline infusion have been widely described. Specifically, a decrease from baseline plasma potassium levels soon after administration of a bolus ( 4 , 5 , 6 ) and an increase in plasma potassium levels up

Introduction Hypokalemia is present when serum levels of potassium are lower than normal. It is a rather common electrolyte disturbance, especially in hospitalized patients, with various causes and sometimes requires urgent medical attention

glucose levels, insulin secretion function and insulin sensitivity in GS patients with both healthy subjects and type 2 DM patients and ( 2 ) observe the serum and urine potassium changes after administration of an oral glucose load. Subjects and

. Regarding other electrolytes and acid-base biomarkers, there are only a few studies published. Low levels of potassium during admission have been associated with poor prognosis and severe disease, but little is known of the dynamics over time in COVID-19

interfering with aldosterone and/or renin levels were stopped and replaced by non-interfering agents for 4–6 weeks ( 1 ). In case of hypokalemia, potassium supplementation was prescribed. Plasma renin concentration (PRC), PAC and potassium concentration were

new predisposing genes would enable earlier detection of pituitary adenomas and therefore improve clinical management of patients. Recently, we showed that two missense mutations in KCNQ1 (potassium voltage-gated channel subfamily Q member 1

plus additional cyproterone acetate and (c) oestradiol plus additional spironolactone. Other parameters of interest included serum oestradiol concentration, potassium, urea and creatinine, haemoglobin, liver function (alanine transaminase (ALT

aldosterone concentration (AC) to lowest plasma potassium ratio ( 21 ). Additionally, Nagano et al. have found the criteria of the plasma aldosterone relative reduction rate and of plasma AC after saline infusion test (SIT) useful to determine which subset

complications are more frequent in untreated thyrotoxicosis ( 2 ). Lugol’s solution (LS) was invented in 1829 by the French physician Jean Guillaume August Lugol as a cure for tuberculosis. It is a solution of elemental iodine (5%), potassium iodide (10%) and

Introduction Over the past two decades, with advances in the understanding of genetic diseases of renal tubular transport defects, there has been greater interest in the importance of potassium in hypertension ( 1 ). Monogenic hypertension